“…BACKGROUND: Vedolizumab was shown to be effective and safe for patients with ulcerative colitis (UC) or Crohn's disease (CD) in the GEMINI phase 3 and long‐term safety (LTS) studies. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Clinical efficacy and health utility were derived from the GEMINI 2 and GEMINI 3 trials and published literature. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We assessed the operating characteristics of ICD-10 discharge diagnostic code U07.1 within the General Medicine Inpatient Initiative (GEMINI). METHODS: GEMINI assembles hospitalization data (including administrative ICD-10 discharge diagnostic codes, laboratory results and demographic data) from hospitals in Ontario, Canada. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Vedolizumab, a gut‐selective α(4)β(7) integrin antibody, is approved for moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Outcome rates were compared with a matched sub-cohort derived from the open-label sub-cohort of the GEMINI 1 trial using the optimal matching method. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The developed LC-MS/MS method showed high reproducibility, as evident from the relative standard deviation (RSD) values for intra-day and inter-day variability being 1.0–6.8% and 2.0–7.7% for phenolic acids and 3.7–7.4% and 1.5–8.1% for flavonoids, respectively, and thus may be applied for simultaneous determination of phenolic acids and flavonoids in Chinese herb and nutraceuticals.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Extraction using water and chloroform resulted in the recovery for cysteamine and cystamine ranging from 100.2–102.7% and 90.6–98.7%, respectively. This validated RP-HPLC method would be useful for quality control and monitoring of cysteamine and cystamine in cosmetics.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The retention time of venlafaxine hydrochloride and carbamazepine were 3.7 min and 5.3 min, respectively. The method was validated for specificity, linearity, accuracy, precision, limit of quantification, limit of detection, robustness and solution stability. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Vedolizumab is a fully humanised monoclonal antibody that selectively targets α4β7 integrin. Based on the results of the pivotal clinical GEMINI trials, vedolizumab was approved for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD) refractory or intolerant to either conventional therapy or TNFα inhibitors. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Among the three compounds, the ellagic acid.(7.65.mg/g) is main component in radix Sanguisorbae. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The proposed HPLC method utilizes Phenomenex Gemini C18 column (150 mm × 4.6 mm i.d., 5 µm) and mobile phase consisting of MeCN, potassium dihydrogen phosphate buffer (20 mM, pH 3.3), and triethylamine 58.72 : 41.23 : 0.05 (v/v) at a flow rate of 1.7 mL/min. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In this study, a novel supramolecular hydrogel system, abbreviated as AGC(16)/NTS, prepared by molecular self-assembly of cationic gemini surfactant 1,3-bis(N,N-dimethyl-N-cetylammonium)-2-propylacrylatedibromide (AGC(16)) and anionic aromatic compound trisodium 1,3,6-naphthalenetrisulfonate (NTS), was used to encapsulate hydrophobic model drug curcumin (Cur), constructing a pH-responsive drug delivery system. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Of patients in clinical remission at week 14, a significantly higher proportion of vedolizumab-treated patients achieved sustained clinical remission compared with placebo (pMS: 66.5% vs 26.7%; ∆39.8%; 95% CI, 22.7–56.9; RBS: 56.7% vs 20.9%; ∆35.7%; 95% CI, 22.3–49.1). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…RESULTS: The incidence of opportunistic infections in patients receiving vedolizumab was 0.7 (GEMINI 1 and 2 clinical trials) and 1.0 (long-term safety study) per 100 patient-years, with 217 events reported in approximately 114,071 patient-years of exposure (post-marketing setting). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The chromatography was conducted using Gemini C18 column (5 μm; 4.6 mm × 250 mm, Phenomenex, California, USA). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Compounds were separated using a Gemini C(18) (250 mm × 4.6 mm, 5 µm) Phenomenex(®) column, at a temperature of 25 °C, with a mobile phase containing 10 mM of phosphoric acid (pH 3.29): acetonitrile (85.7:14.3, v/v) and a flow rate of 1.5 mL/min. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Then, 1,3-dibromopropane was used as the spacer to react with NDPO to form a gemini cationic surfactant, trimethylene α,ω-bis(oleate amide propyl dimethyl ammonium bromide) (GCS). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso